Literature DB >> 19294549

Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery.

J Simon Lunn1, Michael P Hefferan, Martin Marsala, Eva L Feldman.   

Abstract

Amyotrophic lateral sclerosis (ALS) is characterized by loss of both upper and lower motor neurons. ALS progression is complex and likely due to cellular dysfunction at multiple levels, including mitochondrial dysfunction, glutamate excitotoxicity, oxidative stress, axonal dysfunction, reactive astrocytosis, and mutant superoxide dismutase expression, therefore, treatment must provide neuronal protection from multiple insults. A significant amount of ALS research focuses on growth factor-based therapies. Growth factors including insulin-like growth factor-I, vascular endothelial growth factor, brain-derived neurotrophic factor, and glial-derived neurotrophic factor exhibit robust neuroprotective effects on motor neurons in ALS models. Issues concerning growth factor delivery, stability and unwanted side effects slow the transfer of these treatments to human ALS patients. Stem cells represent a new therapeutic approach offering both cellular replacement and trophic support for the existing population. Combination therapy consisting of stem cells expressing beneficial growth factors may provide a comprehensive treatment for ALS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19294549     DOI: 10.1080/08977190902814855

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  16 in total

Review 1.  Using human pluripotent stem cells to untangle neurodegenerative disease mechanisms.

Authors:  Brigitte Malgrange; Laurence Borgs; Benjamin Grobarczyk; Audrey Purnelle; Patricia Ernst; Gustave Moonen; Laurent Nguyen
Journal:  Cell Mol Life Sci       Date:  2010-10-26       Impact factor: 9.261

Review 2.  Intraspinal stem cell transplantation for amyotrophic lateral sclerosis.

Authors:  Kevin S Chen; Stacey A Sakowski; Eva L Feldman
Journal:  Ann Neurol       Date:  2016-02-12       Impact factor: 10.422

Review 3.  Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.

Authors:  Rachna S Pandya; Lilly L J Mao; Edward W Zhou; Robert Bowser; Zhenglun Zhu; Yongjin Zhu; Xin Wang
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-03

Review 4.  Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future.

Authors:  J Simon Lunn; Stacey A Sakowski; Eva L Feldman
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

Review 5.  Translational stem cell therapy for amyotrophic lateral sclerosis.

Authors:  Nicholas M Boulis; Thais Federici; Jonathan D Glass; J Simon Lunn; Stacey A Sakowski; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2011-12-13       Impact factor: 42.937

Review 6.  Stem cell technology for neurodegenerative diseases.

Authors:  J Simon Lunn; Stacey A Sakowski; Junguk Hur; Eva L Feldman
Journal:  Ann Neurol       Date:  2011-09       Impact factor: 10.422

Review 7.  Resveratrol as a therapeutic agent for neurodegenerative diseases.

Authors:  Albert Y Sun; Qun Wang; Agnes Simonyi; Grace Y Sun
Journal:  Mol Neurobiol       Date:  2010-03-21       Impact factor: 5.590

8.  Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.

Authors:  G Yacila; Y Sari
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

9.  Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model.

Authors:  C R Hayworth; F Gonzalez-Lima
Journal:  Neuroscience       Date:  2009-08-20       Impact factor: 3.590

Review 10.  Advances in treatment of neurodegenerative diseases: Perspectives for combination of stem cells with neurotrophic factors.

Authors:  Jie Wang; Wei-Wei Hu; Zhi Jiang; Mei-Jiang Feng
Journal:  World J Stem Cells       Date:  2020-05-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.